The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | A randomized trial of B-RCD versus RCD in WM and a summary of abstracts from this year’s meeting
Pierre Morel, MD, Amiens-Picardie University Hospital Center, Amiens, France, discusses a randomized trial which evaluated bortezomib, rituximab, cyclophosphamide and dexamethasone (B-RCD) versus RCD in patients with Waldenström’s macroglobulinemia (WM). Dr Morel also highlights two abstracts that he presented at this year’s meeting, one which evaluated subsequent mortality in patients with WM compared to the general population, and one which evaluated the prognostic role of depth of response after first-line chemoimmunotherapy in patients with WM. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
